We observed a significant correlation between cerebrospinal fluid (CSF) levels of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of CSF biomarkers, as compared with healthy controls, in a cohort of entirely untreated patients with Parkinson disease (PD) at the earliest stage of the disease studied so far.
T he Parkinson's Progression Markers Initiative (PPMI) was designed to identify Parkinson disease (PD) progression biomarkers and to define subsets of patients with PD by their clinical and biomarker signatures.
1, 2 The PPMI study is a 5-year observational, international, multicenter longitudinal study of drug-naive patients with early-stage idiopathic PD (n = 400) and healthy controls (HCs; n = 200) recruited from 24 selected clinical sites (18 US sites, 5 European sites, and 1 Australian site) with expertise in PD research. These clinical sites were closely assessed by the PPMI steering committee as highly qualified centers to ensure standardization of data acquisition and biospecimen collection. Within the aims of the PPMI study, one of particular interest is to discover biomarkers that identify PD subgroups whose disease progression rates are likely to differ. To meet the objectives of the PPMI study, we evaluated the baseline characteristics of cerebrospinal fluid (CSF) biomarkers (β-amyloid 1-42 [Aβ1 -42] , total tau [T-tau], tau phosphorylated at threonine 181 [P-tau 181 ], and α-synuclein [α-syn]) in patients with PD and HCs and the relationship between CSF biomarkers and clinical features of PD in the initial 102 subjects enrolled at 15 clinical sites. The implementation of standardized procedures including preanalytical and analytical steps involved in the acquisition of CSF, aliquoting, storage at −80°C, and assessment of hemolysis by measurement of hemoglobin (Hb) in each collected sample has been important to the study. Among several subtypes of PD defined on the basis of clinical characteristics as well as underlying neuropathology, [3] [4] [5] [6] cognitive impairment in PD, which is a common nonmotor comorbidity, progresses to overt dementia in approximately 80% of patients with PD, with wide variations in duration from onset of PD to the emergence of dementia onset. [7] [8] [9] [10] For several reasons, including the increased cost of care and the higher mortality rate in PD with dementia compared with nondemented patients with PD, 11, 12 early prediction of dementia is critical to the clinical management of patients with PD as well as to stratifying patients at highest risk for dementia in clinical trials of disease-modifying therapies that could slow dementia onset and progression. A motor phenotype dominated by postural instability-gait disturbance (PIGD) has been associated with more rapid cognitive decline and/or more functional disability in patients with PD compared with the tremordominant (TD) PD phenotype. 3, [13] [14] [15] [16] Cerebrospinal fluid measurements of Aβ1-42, T-tau, and P-tau 181 are widely recognized as sensitive and specific assays for the early diagnostic distinction of patients with Alzheimer disease (AD) from cognitively normal individuals, for predicting the progression from mild cognitive impairment to AD, and for discriminating AD-vs non-AD-type neurodegenerative diseases. [17] [18] [19] [20] [21] [22] [23] Several studies have reported that CSF Aβ1-42 levels in patients with PD with or without dementia are lower than in HCs [24] [25] [26] [27] [28] [29] and recent data show that CSF levels of T-tau or P-tau 181 in patients with PD are significantly lower than those in HCs, [28] [29] [30] but other data do not confirm such differences. [24] [25] [26] [27] 31 The reasons for such discrepancy may include but not are limited to methodologic variables including CSF processing, the biomarker assays used, and the diversity in criteria for elderly controls and in the stage of PD across the studies. Interestingly, a recent prospective cohort study with 2 years of longitudinal follow-up evaluation suggested that reduced concentration of CSF Aβ1-42 (≤192 pg/mL), but not T-tau or P-tau 181 , is an independent predictor of cognitive decline in patients with PD. 32 Cerebrospinal fluid α-syn concentrations may be reduced in PD and related disorders compared with healthy subjects. 29, 31, 33 However, to our knowledge, studies evaluating the association of these CSF biomarkers measured using validated and standardized methods in study subjects with clinical features of patients with very early-stage PD enrolled at multinational qualified clinical sites are very limited. Therefore, the simultaneous measurement of Aβ1-42, T-tau, P-tau 181 , and α-syn in CSF of PPMI study subjects may provide diagnostic value and/or biological insight for progression of disease in patients with early-stage PD. Moreover, although previous studies have revealed an association between α-syn and tau or Aβ1-42 in vitro and in transgenic animals, [34] [35] [36] there is no report to our knowledge describing the relationship between AD-related biomarkers and α-syn in human antemortem CSF samples from patients with PD and HCs. We hypothesized that measurement of Aβ1-42, T-tau, P-tau 181 , and α-syn in CSF can differentiate patients with early-stage PD from demographically matched HCs and can reflect the heterogeneity of clinical features of PD. To test our hypothesis, we report the CSF profile of Aβ1-42, T-tau, P-tau 181 , and α-syn in the initial 102 PPMI subjects and assess whether specific clinical features of PD are associated with distinct biomarker signatures for Aβ1-42, T-tau, P-tau 181 , and α-syn in untreated patients with PD at the earliest stage of the disease studied so far.
Methods

Participants
The PPMI study is an ongoing international multicenter study involving PD centers in Europe, Australia, and the United States as described in detail elsewhere 2 and at the PPMI website (http:
symptoms and provided CSF at the BL visit (n = 4) were excluded from the PD group, and their data were also excluded from further statistical analyses in this report. 
Analysis of CSF Biomarkers
Measurements of Aβ1-42, T-tau, and P-tau 181 were taken in each of 102 CSF aliquots at the University of Pennsylvania using the multiplex Luminex xMAP platform (Luminex Corp) with research-use-only Fujirebio-Innogenetics INNO-BIA AlzBio3 immunoassay kit-based reagents (Innogenetics Inc) of a single lot as described previously. 17, 39 All standards, aqueous controls, and CSF samples (including 2 CSF pools for quality control, 75 μL of each) were analyzed in duplicate in each run as described. 17, 39 A result was defined as the arithmetic mean of the calculated concentration of duplicates. Cerebrospinal fluid α-syn was analyzed at Covance using a commercially available enzyme-linked immunosorbent assay kit (Covance) that was developed and optimized from an assay previously described. 31, 40 Briefly, 200 μL/ well of diluted α-syn standards (range, 6.1-1500 pg/mL) using reconstituted stock and diluted duplicate CSF samples (200 μL/ well) were added to the capture antibody-coated plate after washing the plate 4 times. After overnight incubation of the plate at 2°C to 8°C with shaking, 50 μL/well of biotinylated detector antibody was added followed by incubation for 2 hours at room temperature. Diluted streptavidin horseradish peroxidase was added, and the plate was incubated at room temperature for an additional 1 hour. After washing the plate 4 times, a mixture of 2 different chemiluminescent substrates was added and endpoint luminescence was read with a luminometer (Synergy 2; BioTek). The concentration of α-syn was measured using standard curves with 4-parameter curve fitting. There is no crossreactivity of the antibodies used in this enzyme-linked immunosorbent assay with β-syn or γ-syn. 31, 40 Cerebrospinal fluid Hb was analyzed at Covance using an enyzme-linked immunosorbent assay method with reagents obtained from Bethyl Laboratories according to the manufacturer's instruction. This was done to evaluate the quality of CSF collection, to use as an index of the degree of blood contamination, and to control for the possible effect of hemolysis on the CSF α-syn level. 33 After completion of these CSF biomarker analyses, the code for each of the subjects was opened.
Statistical Analysis
Statistical analysis was performed using SAS version 9.3 (SAS Institute, Inc) and GraphPad Prism version 5.0 (GraphPad Software, Inc) statistical software. Mann-Whitney U test was used to assess differences between 2 groups, and Kruskal-Wallis test with Dunn correction was used for multiple comparisons for 3 or more groups. All patient data included in this study were simultaneously downloaded by 2 laboratories (University of Pennsylvania and University of Iowa), which agreed on statistical analyses performed independently. The correlations were evaluated using linear regression analysis (Pearson correlation). The analyses were also done using an analysis of covariance model to check our results after controlling for possible confounding variables, ie, age, sex, and education. To explore the association between biomarkers and clinical variables, we used multivariate logistic regression (MLGR) or multivariate linear regression models and adjusted for confounding factors (age, sex, and education). The diagnostic utility of each biomarker (sensitivity and specificity) was determined by receiver operating characteristic curve analysis using cut points giving the highest Youden index, [sensitivity + specificity] − 1. 41 Differences in percentage of subjects in each group were evaluated by χ 2 test. Values with P < .05 were regarded as statistically significant.
Results
Analytical Performance of CSF Biomarkers Measurement
The analytical performance of the Luminex xMAP platform and AlzBio3 immunoassay research-use-only reagents for AD CSF biomarkers in PPMI subjects was comparable to that reported in our earlier studies. 17, 39 The mean percentage coefficients of variation across 4 runs of Aβ1-42, T-tau, and P-tau 181 measurement were 3.8%, 5.6%, and 4.4% for aqueous controls and 7.5%, 6.4%, and 3.0% for 2 CSF pools, respectively. The analytical performance of α-syn measurement by enzyme-linked immunosorbent assay showed that the mean percentage coefficient of variation for duplicates of α-syn measurements was 6.0% for 102 CSF samples (range, 0.8%-13.2%), and the mean percentage coefficient of variation of 8 calibrators through 11 runs was 7.9% (range, 6.9%-9.8%).
Demographic Information and Effects of Age, Sex, and CSF Hb
There were no significant differences in mean age, sex distribution, educational level, and median CSF Hb concentration between HCs and patients with PD ( Table 1) . The median duration from diagnosis of PD to BL was 0.4 years, and the Hoehn and Yahr stage of the patients was limited to I or II at BL. Previous studies demonstrated that contamination of blood in CSF could have an influence on the level of some proteins, including α-syn and Aβ1-42.
29,33 Therefore, we evaluated the relationship between the CSF biomarkers and CSF Hb levels. No association was observed between levels of CSF Hb and T-tau, P-tau 181 , or Aβ1-42, consistent with earlier reports that there is no effect of added blood on measured concentrations of these biomarkers. 33, 42 The CSF α-syn level was modestly increased by CSF Hb contamination at concentrations higher than 1000 ng/mL. A trend toward increasing values of α-syn was observed at very high CSF Hb concentrations (Pearson r = 0.3975; P < .001) (eFigure in Supplement). 
Comparison of Clinical Characteristics Between HCs and Patients With PD
Comparison of CSF Biomarkers Between HCs and Patients With PD
Comparisons of CSF biomarker concentrations between patients with PD and HCs are summarized in Table 3 . Because we observed a small but significant correlation between CSF Hb and α-syn levels in 102 subjects, we stratified subjects by their CSF Hb levels. We observed that CSF α-syn levels in patients with PD were significantly lower than those in HCs (P = .01), and this was still observed after exclusion of subjects with CSF Hb levels higher than 200 ng/mL (P = .02) or 500 ng/mL (P = .007) (Figure 1) . Levels of Aβ1-42, P-tau 181 , T-tau, and T-tau/Aβ1-42 Research Original Investigation Aβ1-42, T-tau, P-tau 181 , α-Synuclein, and PD were significantly lower in the PD group as compared with HCs ( Figure 2) , although significant overlap in levels of CSF biomarkers between patients with PD and HCs was observed.
Correlation Between α-Syn and Tau Proteins in CSF
As shown in Figure 3 , CSF α-syn levels strongly correlated with measures of CSF T-tau in both patients with PD (Pearson r = 0.7899; P < .001) and HCs (Pearson r = 0.6863; P < .001). The correlation between levels of CSF α-syn and P-tau 181 also was significant in both patients with PD (Pearson r = 0.5481; P < .001) and HCs (Pearson r = 0.3173; P = .049), but the correlations were weaker than for CSF T-tau. There was no correlation between measures of CSF Aβ1-42 and α-syn in either group (r = 0.1553 for patients with PD and r = −0.0450 for HCs).
Association of CSF Biomarkers With PD Diagnosis and Motor Severity of PD
As part of the process of development of an MLGR model for the association of CSF biomarkers with PD diagnosis, we first performed bivariate analysis of each CSF biomarker and PD clinical features along with adjustment for confounders (age, sex, and education). This step revealed that CSF T-tau (P = .02), P-tau 181 (P = .005), and α-syn (P = .04) were significantly associated with PD diagnosis. However, when the stepwise selection method was used to generate the final MLGR model, including all CSF biomarkers with adjustment for confounders, only lower levels of CSF Aβ1-42 (odds ratio = 1.010; 95% CI, 1.001-1.020; P = .04) and P-tau 181 (odds ratio = 1.102; 95% CI, 1.038-1.170; P = .002) were significantly associated with PD diagnosis. When we used receiver operating characteristic curve analyses to calculate sensitivity and specificity to differentiate patients with PD from HCs, the area under the receiver operating characteristic curve for each CSF biomarker for PD diagnosis was relatively low, consistent with a previous study (data not shown).
29
Using multivariate linear regression analysis with adjustment for confounders to explore the association of CSF biomarkers with motor severity of patients with PD, we found that α-syn (β = 0.00679 [SE = 0.00247]; P = .008) was significantly associated with the Movement Disorder Societysponsored revision of the Unified Parkinson's Disease Rating Scale part III motor score and T-tau was marginally associated (β = −0.14771 [SE = 0.07111]; P = .04). The CSF α-syn level was marginally associated with Hoehn and Yahr stage (β = −0.00021269 [SE = 0.0001044]; P = .046). However, no CSF biomarkers were significantly associated with cognitive function test scores. Each group was differentiated according to their cerebrospinal fluid hemoglobin concentration to total subjects (A), subjects with a cerebrospinal fluid hemoglobin concentration less than 500 ng/mL (B), and subjects with a cerebrospinal fluid hemoglobin concentration less than 200 ng/mL (C , and sex distribution (male to female ratio, 7:7 vs 29:14 and 3:3, respectively). When we compared the CSF biomarkers studied here between patients with PIGD-PD and those with TD-PD, CSF Aβ1-42 and P-tau 181 levels in those with PIGD-PD were significantly lower than in those classified as having TD-PD (Table 4) . Moreover, CSF α-syn levels in the subjects with PIGD-PD were lower than those in the TD-PD group, albeit with only marginal significance (P = .06), but this reached statistical significance when patients with CSF Hb levels greater than 200 ng/mL were excluded (P = .03). Interestingly, when we compared levels of CSF biomarkers among patients with TD-PD, PIGD-PD, and IND-PD and HCs, levels of all CSF biomarkers (not including T-tau/Aβ1-42, P-tau 181 /Aβ1-42, and P-tau 181 /T-tau ratios) in those with PIGD-PD were significantly lower than in HCs, while those in patients with TD-PD or IND-PD were comparable to those in HCs (Kruskal-Wallis test with correction for multiple comparisons using Dunn test). In addition, we found that lower levels of CSF Aβ1-42 and P-tau 181 were significantly associated with the PIGD motor phenotype, with odds ratios of 1.023 (95% CI, 1.006-1.040; P = .008) and 1.124 (95% CI, 1.014-1.247; P = .03), respectively, using MLGR analysis with adjustment for confounders.
Discussion
To minimize the preanalytical and analytical variability in CSF biomarker measurement and to assure the quality of this study, we performed the research described here using highly standardized procedures (eg, use of siliconized polypropylene CSF aliquot tubes, centralized analyses of CSF biomarkers, and assessment of blood contamination by CSF Hb measurement). The quality of CSF biomarker measurements in this study is supported by the observed consistency (low run-to-run percentage coefficient of variation) for the CSF biomarker levels and control for the possible influence of hemolysis on α-syn values. Research Original Investigation Aβ1-42, T-tau, P-tau 181 , α-Synuclein, and PD This study is the first cross-sectional report on CSF biomarkers (Aβ1-42, T-tau, P-tau 181 , and α-syn) in PPMI subjects. We found several characteristics of CSF biomarkers related to clinical features of early-stage PD in this study. First, the levels of CSF Aβ1-42, T-tau, P-tau 181 , T-tau/Aβ1-42, and α-syn in patients with PD were significantly lower than those in demographically matched HCs, and CSF Aβ1-42 and P-tau 181 levels differentiated patients with PD from HCs in our MLGR model. Second, the observed PD-associated lower levels of CSF Aβ1-42, T-tau, P-tau 181 , and α-syn may be driven primarily by the PIGD-PD subgroup since these biomarkers were lower in the patients with PIGD-PD vs HCs but did not differ comparing HCs and patients with TD-PD or IND-PD. Third, CSF T-tau and α-syn concentrations were significantly associated with severity of motor dysfunction in PD. Finally, we found that CSF α-syn levels had a strong correlation with the levels of CSF tau proteins (T-tau and P-tau 181 ), particularly in patients with PD.
In contrast to AD, we observed lower levels of tau proteins in CSF of patients with PD as compared with HCs, which is consistent with the results of some 28, 29 but not all prior studies. [24] [25] [26] [27] To our knowledge, the PPMI cohort is the first cohort of entirely untreated subjects with PD to demonstrate a reduction in tau proteins compared with HCs. Similar to AD, albeit with different magnitudes, our study, like several previous studies, detected lower levels of CSF Aβ1-42 in patients with PD compared with HCs, [24] [25] [26] [27] [28] [29] and lower levels of CSF Aβ1-42 have been reported to be associated with rapid decline of cognitive function in PD. 32 One interpretation for lower concentration of CSF tau proteins in our patients with early PD is that the interaction between tau proteins and other proteins including α-syn may limit the release of tau proteins into CSF. It is interesting to note that lower CSF concentrations are observed in other neurodegenerative disorders as shown for frontotemporal lobar degeneration, 21, 43 suggesting that the observed lowering of these biomarkers that traditionally reflect neurodegeneration is caused by an as yet unknown pathophysiological mechanism. In connection with our finding of a strong correlation between CSF tau proteins (T-tau and P-tau 181 ) and α-syn, particularly in patients with PD (Figure 3 ), previous studies using animal models or postmortem brain report that CNS α-syn pathology is accompanied by increased levels of hyperphosphorylated tau proteins. [44] [45] [46] [47] Indeed, tau-positive tangles and α-syn-positive Lewy bodies may colocalize in the same neuron in AD brains, 48 while both cross seed the fibrillization of each other. 35 Moreover, a recent genome-wide association study demonstrated significant genetic association with PD of the genes MAPT and SNCA encoding tau and α-syn, respectively. 49 Thus, taken together, these findings are consistent with the notion that the deposition of α-syn in the PD brain may cause the decrease of α-syn in CSF of patients with PD and also may inhibit the release of tau proteins into CSF by unknown molecular mechanisms. Our finding of a significant correlation between T-tau and α-syn in HCs could result from the same putative mechanism suggested for the situation in subjects with PD. However, there is little direct evidence that α-syn interacts with tau proteins at the molecular level in the brain of patients with PD, 46,47,50 although evidence for this has been reported in transgenic mouse models of PD-like α-syn pathology. 35 The results of our study suggest an interaction between tau and α-syn in the brain of cognitively normal elderly subjects based on the result of significant correlation between these 2 biomarkers observed in the HC group. We believe that this result does not contradict the hypothetical pathophysiological relationship between α-syn and tau since Lewy body pathology is frequently found in elderly subjects with normal cognitive function, 51 and thus the CSF α-syn correlation with tau proteins' concentration in HCs is consistent with the observed pathology in elderly cognitively normal subjects. Further evidence for direct and/or indirect physiological and pathological interaction between α-syn and tau proteins in human brain will be needed to explain the simultaneous decrease of CSF tau proteins and α-syn in subjects with PD as compared with HCs. Consistent with previous reports, 29, 31, 33 the diagnostic utility of CSF α-syn or Aβ1-42, T-tau, or P-tau 181 to differentiate patients with PD from HCs is low. Although the levels of CSF Aβ1-42 and P-tau 181 are significantly associated with PD diagnosis, neither biomarker had an area under the receiver operating characteristic curve greater than 0.8 for PD diagnosis. The combination of other biomarkers including genetic markers and plasma or CSF measures of DJ-1, for example, will also likely be necessary to improve the diagnostic utility of the CSF biomarkers studied here.
29,33
Intriguingly, we found that several CSF proteins measured here may be promising biomarkers for a specific motor endophenotype within PD-the PIGD-PD motor subtype. Specifically, lower CSF Aβ1-42, T-tau, P-tau 181 , and α-syn concentrations were found in the individuals with the PIGD-PD motor subtype, and in an MLGR model, CSF Aβ1-42 and P-tau 181 levels were significantly associated with PIGD-PD. Consistent with these results was the recent report of lower CSF Aβ1-42 level in the PIGD phenotype of newly diagnosed and untreated patients with PD as compared with the TD phenotype or HCs, although the motor phenotype was assessed by the Unified Parkinson's Disease Rating Scale instead of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale that we used in this study. 52 The significance of this finding is that the PIGD-PD mo- tor subtype has been reported to progress more quickly, 3, 13, 16 along both motor and nonmotor trajectories. Albeit preliminary, our findings are particularly important as our patients are in early stages of PD and many subjects have not fully "declared" themselves as having either PIGD-PD or TD-PD. Since the data suggest that these CSF protein patterns may be able to differentiate between the various motor subtypes even in early stages of PD, they may turn out to be promising biomarkers of differential trajectories of PD progression. However, we recognize that further studies in the PPMI cohort with a large number of subjects with each motor phenotype are needed to adequately address this question.
Several limitations of our study should be noted. This is a cross-sectional study using data from the initial 102 subjects from the PPMI study cohort, thereby limiting our ability to determine the relationships between the CSF biomarkers studied here and disease progression. In addition, we did not evaluate genetic factors or other biomarker candidates, including DJ-1. However, these limitations will be resolved in future PPMI analyses.
In conclusion, based on this first report of our analyses of CSF Aβ1-42, T-tau, P-tau 181 , and α-syn biomarkers in the first 102 members of the PPMI cohort, our results demonstrate that the levels of AD-related CSF biomarkers (Aβ1-42, T-tau, and P-tau 181 ) and CSF α-syn in drug-naive patients with early-stage PD are lower than those in demographically similar HCs. Furthermore, CSF Aβ1-42 and P-tau 181 are significant predictors of PD vs HCs and T-tau and α-syn are associated with severity of motor dysfunction in early PD. Although further study using the full PPMI data set is necessary to validate the current results, patients with PD who have lower CSF Aβ1-42, P-tau 181 , and α-syn levels are more likely to have the PIGD-dominant motor phenotype, which has been associated with more rapid disease progression. These results provide evidence for the potential value of these CSF biomarkers for the diagnosis and assessment of heterogeneous disease progression in early-stage PD and suggest biomarker strategies for the possible recognition of prodromal PD similar to what is being pursued with AD biomarkers. 22 
